Pancreatic cancer is one of the most serious and difficult cancers to treat. It often develops quietly, with few symptoms in the early stages.
By the time it is found, the disease has usually spread, making treatment much harder. Because of this, survival rates remain low, and doctors are still searching for better ways to treat it.
Now, scientists from The Wistar Institute and researchers from ChristianaCare have made an important discovery. Their study, published in the Proceedings of the National Academy of Sciences, has identified a hidden weakness inside pancreatic cancer cells. This weakness could become a new target for treatment in the future.
To understand this discovery, it helps to know a little about how cells work. Inside every cell are small structures called mitochondria. These are often described as the “power stations” of the cell because they produce energy. In healthy cells, mitochondria are well-organized and protected by a strong outer layer.
However, in many cancer cells, these mitochondria are damaged. The researchers found that in pancreatic cancer, the mitochondria are missing an important structural protein called Mic60. Without this protein, the mitochondria become unstable and start to break down.
Instead of working normally, these damaged mitochondria begin to leak material into the cell. One of the substances they release is something called double-stranded RNA. Normally, this type of RNA is linked to viral infections, so the cell treats it as a danger signal.
When the cell detects this signal, it activates a strong immune response. This process involves two important molecules called TLR3 and TRAF6. These molecules act like sensors, detecting the leaked RNA and triggering inflammation inside the cell.
Inflammation is usually part of the body’s defense system. It helps fight infections and repair damage. But in this case, the cancer cells use inflammation to their advantage. The inflammation creates an environment that helps the cancer grow and spread.
The researchers discovered something even more surprising. Over time, the cancer cells become dependent on this inflammation. They rely on it not only to grow but also to survive. This means that if the inflammation is blocked, the cancer cells can no longer live.
To test this idea, scientists used drugs to block the TLR3 and TRAF6 pathway. When this pathway was turned off, the cancer cells died, while healthy cells remained mostly unaffected. In animal studies, this approach also stopped tumor growth.
This finding is important because it reveals a new way to attack cancer. Instead of directly killing cancer cells, the treatment removes something the cancer depends on. This could lead to more targeted therapies with fewer side effects.
However, it is important to be careful when interpreting these results. The study was done mainly in laboratory and animal models. More research is needed to confirm that the same approach will work in humans. Scientists also need to develop safe and effective drugs that can block this pathway.
Even with these limitations, the discovery is very promising. Pancreatic cancer has long been known as a disease with few treatment options. Finding a new target gives researchers a fresh direction to explore.
In the future, scientists hope to better understand how the loss of Mic60 damages mitochondria and triggers this process. They also aim to develop drugs that can safely block the TLR3/TRAF6 pathway in patients.
In summary, this study reveals that pancreatic cancer may have a hidden weakness linked to inflammation caused by damaged mitochondria. While more work is needed, the findings offer new hope for developing better treatments for this challenging disease.
If you care about cancer, please read studies that a low-carb diet could increase overall cancer risk, and berry that can prevent cancer, diabetes, and obesity.
For more health information, please see recent studies about how drinking milk affects the risks of heart disease and cancer and results showing vitamin D supplements could strongly reduce cancer death.
Source: The Wistar Institute.
